Diego
Pérez Parente
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications in collaboration with researchers from Hospital Universitario Marqués de Valdecilla (1)
2023
-
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
Cost Effectiveness and Resource Allocation, Vol. 21, Núm. 1